A Detailed Protocol for Generation of Therapeutic Antibodies with Galactosylated Glycovariants at Laboratory Scale Using In-Vitro Glycoengineering Technology
Authors:
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 110 (2) , 935-945
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb Canada
This publication has 28 references indexed in Scilit:
- Antibody Glycosylation and InflammationAntibodies, 2013
- Glycoproteomic Analysis of AntibodiesMolecular & Cellular Proteomics, 2013
- Development and qualification of an antibody rapid deglycosylation methodBiologicals, 2012
- Engineering novel Lec1 glycosylation mutants in CHO–DUKX cells: Molecular insights and effector modulation of N‐acetylglucosaminyltransferase IBiotechnology and Bioengineering, 2012
- Structure and function of immunoglobulinsJournal of Allergy and Clinical Immunology, 2010
- A close look at human IgG sialylation and subclass distribution after lectin fractionationProteomics, 2009
- Glycosylation as a strategy to improve antibody-based therapeuticsNature Reviews Drug Discovery, 2009
- Glycosylation profiling of immunoglobulin G (IgG) subclasses from human serumProteomics, 2007
- The Impact of Glycosylation on the Biological Function and Structure of Human ImmunoglobulinsAnnual Review of Immunology, 2007
- Post-translational modifications in the context of therapeutic proteinsNature Biotechnology, 2006